Neutropenia  >>  Rolvedon (eflapegrastim-xnst)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rolvedon (eflapegrastim-xnst) / Assertio
SPI-GCF-12-201, NCT01724866 / 2013-003094-10: Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

Completed
2
148
Europe, US, RoW
SPI-2012, Rolontis®, HM10460A, Eflapegrastim, Pegfilgrastim, Neulasta®, Docetaxel, Taxotere, Cyclophosphamide, Cytoxan
Spectrum Pharmaceuticals, Inc
Neutropenia
08/14
08/14
NCT04570423: A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Recruiting
2
40
US
Eflapegrastim, Rolontis®, SPI-2012, Chemotherapy
Spectrum Pharmaceuticals, Inc
Solid Tumors, Lymphoma
10/27
10/27

Download Options